{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:46:41Z","timestamp":1793936801867,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.antiviral.2018.10.003","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T11:38:09Z","timestamp":1538825889000},"page":"143-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease"],"prefix":"10.1016","volume":"159","author":[{"given":"Eiichi","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-1418","authenticated-orcid":false,"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Dohmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeaki","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Koyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritsune","family":"Ooho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.10.003_bib1","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1111\/apt.14639","article-title":"Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study","volume":"47","author":"Anty","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2018.10.003_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/hepr.13058","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease","volume":"48","author":"Arai","year":"2018","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.antiviral.2018.10.003_bib3","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1478-3231.2010.02235.x","article-title":"Comorbidities associated with the increasing burden of hepatitis C infection","volume":"30","author":"Basseri","year":"2010","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2018.10.003_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.ajkd.2010.09.023","article-title":"HCV infection and the incidence of CKD","volume":"57","author":"Butt","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.antiviral.2018.10.003_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/apt.14799","article-title":"Effectiveness, treatment completion and safety of sofosbuvir\/ledipasvir and paritaprevir\/ritonavir\/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study","volume":"48","author":"Butt","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2018.10.003_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"Chen","year":"2006","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.antiviral.2018.10.003_bib7","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJMra1208642","article-title":"Therapy for hepatitis C virus-related cryoglobulinemic vasculitis","volume":"369","author":"Dammacco","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.10.003_bib8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/hep.1840360621","article-title":"Extrahepatic manifestations of hepatitis C among United States male veterans","volume":"36","author":"El-Serag","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.10.003_bib9","first-page":"151","article-title":"High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied","volume":"54","author":"Espinosa","year":"2000","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.antiviral.2018.10.003_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.10.003_bib11","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","article-title":"Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.10.003_bib12","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/apt.14635","article-title":"Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network","volume":"47","author":"Flamm","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2018.10.003_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12945","article-title":"Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir\/paritaprevir\/ritonavir\u00b1dasabuvir\u00b1ribavirin in the AMBER, real-world experience study","author":"Flisiak","year":"2018","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2018.10.003_bib14","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.10.003_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/nep.13222","article-title":"Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with eGFR<30 ml\/min","author":"Goel","year":"2018","journal-title":"Nephrology"},{"key":"10.1016\/j.antiviral.2018.10.003_bib16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","article-title":"Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study","volume":"61","author":"Gragnani","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.10.003_bib17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.10.003_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2018.10.003_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12937","article-title":"Real-world effectiveness of elbasvir\/grazoprevir in HCV-infected patients in the US veterans affairs healthcare system","author":"Kramer","year":"2018","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2018.10.003_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01249-18","article-title":"Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan","volume":"62","author":"Krishnan","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.003_bib21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00535-016-1285-y","article-title":"The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II\/III study","volume":"52","author":"Kumada","year":"2017","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.10.003_bib22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection","volume":"53","author":"Kumada","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.10.003_bib23","article-title":"Generic sofosbuvir\u2010based direct\u2010acting antivirals in hepatitis C virus\u2010infected patients with chronic kidney disease","author":"Kumar","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2018.10.003_bib24","first-page":"259","article-title":"Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues","volume":"11","author":"Marcellin","year":"2017","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2018.10.003_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.antiviral.2009.04.002","article-title":"The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin","volume":"83","author":"Ogawa","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.003_bib26","doi-asserted-by":"crossref","first-page":"E120","DOI":"10.1111\/hepr.12738","article-title":"Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis","volume":"47","author":"Ogawa","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.antiviral.2018.10.003_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/apt.14380","article-title":"Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment","volume":"47","author":"Ogawa","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2018.10.003_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12072-018-9859-9","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment","volume":"12","author":"Okubo","year":"2018","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2018.10.003_bib29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(11)60242-0","article-title":"The cryoglobulinaemias","volume":"379","author":"Ramos-Casals","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.10.003_bib30","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/hepr.12899","article-title":"Elbasvir\/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease","volume":"47","author":"Reddy","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.antiviral.2018.10.003_bib31","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.10.003_bib32","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1159\/000488965","article-title":"Paritaprevir\/ritonavir\/ombitasvir plus dasabuvir regimen in the treatment of genotype 1 chronic hepatitis C infection in patients with severe renal impairment and end-stage renal disease: a real-life cohort","volume":"43","author":"Sperl","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.antiviral.2018.10.003_bib33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","article-title":"Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan","volume":"53","author":"Suda","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.10.003_bib34","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1007\/s10620-018-4979-6","article-title":"Low-dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease","volume":"63","author":"Taneja","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.antiviral.2018.10.003_bib35","series-title":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C","author":"The AASLD and IDSA","year":"2018"},{"key":"10.1016\/j.antiviral.2018.10.003_bib36","doi-asserted-by":"crossref","DOI":"10.1007\/s00535-018-1473-z","article-title":"Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan","author":"Toyoda","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.10.003_bib37","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/archinte.167.12.1271","article-title":"Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease","volume":"167","author":"Tsui","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.10.003_bib38","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T10:37:55Z","timestamp":1544006275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218305126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":38,"alternative-id":["S0166354218305126"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}